In a recent post on the IVI-sponsored Health Affairs featured blog series, Anupam Jena and IVI Strategic Advisory Panel member, Sachin Kamal-Bahl, examine the spillover effects of healthcare for patients’ families. These family spillover benefits, they argue, may be significant. For example, a parent of a blind child would likely be willing to pay far more than the expected economic cost of the child’s care to cure their blindness. Jena and Kamal-Bahl argue that such spillovers should be considered when assessing the overall value of a therapy or intervention.

Read the full article here.

About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.